Project Grant R01AI183353
Award Date
8/9/24
Completion Date
7/31/29
Dollars Obligated
$137K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Thailand
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,504,456 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Chicago. The 5-year grant, awarded on August 15, 2024, will support research using artificial intelligence to bridge human and murine studies of lupus nephritis progression. Specifically, the project aims to investigate tubulointerstitial hypoxia, metabolic dysfunction, capillary rarefaction, immune...
This Project Grant award of $1,211,704.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund comprehensive studies to elucidate the pathogenesis of severe dengue disease during primary infections. The research aims to determine differences in innate, antibody, and T-cell immune responses between severe primary and secondary dengue infections. The grant will leverage state-of-the-art tools and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $120,226 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Fundacao De Apoio A Pesquisa E A Extensao (Fapex), a non-profit research organization based in Brazil. This 5-year grant, effective from August 2024 to July 2029, supports research investigating the relationship between adipose tissue, inflammation, and the clinical outcomes of cutaneous leishmaniasis in obese patients. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $267,168 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Institut Pasteur DU Cambodge, a non-profit research establishment in Phnom Penh, Cambodia. The grant aims to leverage access to Plasmodium vivax (P. vivax) parasite diversity to identify culture-adaptable strains and develop robust in vitro culture systems. This would enable advanced studies on P. vivax malaria, which poses...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $369,431 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Wisconsin-Eau Claire. The grant, awarded on August 21, 2024, supports a project titled "Molecular Determinants and Behavioral Fingerprints of Schistosome Miracidia Host-Seeking". The project aims to quantitatively describe the host-seeking behaviors of schistosome miracidia, the aquatic larval...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,663,244 project grant under CFDA 93.855, Allergy and Infectious Diseases Research, to President and Fellows of Harvard College (Harvard Medical School) on March 1, 2025. The project aims to characterize innate immune signaling pathways in the tick Ixodes scapularis, which is a vector for Lyme disease and other emerging infectious diseases. The research will combine cell culture-based methods with in vivo assays in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,248,576 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. The grant, awarded on July 25, 2025, will fund research to understand the cross-protective efficacy of the recently FDA-approved IXCHIQ live attenuated chikungunya virus vaccine against other alphavirus species, assess the vaccine's infectivity and transmissibility in mosquitoes, and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,170,041 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Hawaii (UH) to study the long-term safety and effectiveness of the Dengvaxia dengue vaccine in the Philippines. The key objectives are to determine the baseline dengue virus serostatus of Dengvaxia recipients, assess the long-term safety and effectiveness of the vaccine, and characterize the antibody and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $204,347 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Vermont & State Agricultural College to study the intracellular colonization strategies of Salmonella enterica serovar Typhimurium within human intestinal epithelial cells and macrophages. The research aims to characterize bacterial and host transcripts during Salmonella infection, distinguish between cytosolic and...